Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.

Zangari M, Berno T, Yang Y, Zeng M, Xu H, Pappas L, Tricot G, Kamalakar A, Yoon D, Suva LJ.

Bone. 2014 Apr;61:39-43. doi: 10.1016/j.bone.2013.12.025. Epub 2013 Dec 31.

2.

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN.

Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5.

3.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ.

Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

4.

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.

Kraus M, Bader J, Geurink PP, Weyburne ES, Mirabella AC, Silzle T, Shabaneh TB, van der Linden WA, de Bruin G, Haile SR, van Rooden E, Appenzeller C, Li N, Kisselev AF, Overkleeft H, Driessen C.

Haematologica. 2015 Oct;100(10):1350-60. doi: 10.3324/haematol.2014.109421. Epub 2015 Jun 11.

5.

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C.

Cancer Chemother Pharmacol. 2015 Aug;76(2):383-96. doi: 10.1007/s00280-015-2801-0. Epub 2015 Jun 23.

6.

Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.

Zang M, Li Z, Liu L, Li F, Li X, Dai Y, Li W, Kuckelkorn U, Doeppner TR, Hermann DM, Zhou W, Qiu L, Jin F.

Cancer Lett. 2015 Oct 1;366(2):173-81. doi: 10.1016/j.canlet.2015.06.011. Epub 2015 Jun 23.

PMID:
26116344
7.

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.

Niewerth D, Kaspers GJ, Assaraf YG, van Meerloo J, Kirk CJ, Anderl J, Blank JL, van de Ven PM, Zweegman S, Jansen G, Cloos J.

J Hematol Oncol. 2014 Jan 13;7:7. doi: 10.1186/1756-8722-7-7.

8.

Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.

Edwards CM, Lwin ST, Fowler JA, Oyajobi BO, Zhuang J, Bates AL, Mundy GR.

Am J Hematol. 2009 May;84(5):268-72. doi: 10.1002/ajh.21374.

9.

The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE.

Autophagy. 2012 Dec;8(12):1873-4. doi: 10.4161/auto.22185. Epub 2012 Sep 20.

10.

Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.

Tagoug I, Jordheim LP, Herveau S, Matera EL, Huber AL, Chettab K, Manié S, Dumontet C.

Clin Cancer Res. 2013 Jul 1;19(13):3556-66. doi: 10.1158/1078-0432.CCR-12-3134. Epub 2013 May 14.

11.

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2010 Jul 21;102(14):1069-82. doi: 10.1093/jnci/djq198. Epub 2010 May 26.

PMID:
20505154
12.

Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells.

Dasgupta S, Castro LM, Dulman R, Yang C, Schmidt M, Ferro ES, Fricker LD.

PLoS One. 2014 Jul 31;9(7):e103604. doi: 10.1371/journal.pone.0103604. eCollection 2014.

13.

Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.

Shabaneh TB, Downey SL, Goddard AL, Screen M, Lucas MM, Eastman A, Kisselev AF.

PLoS One. 2013;8(2):e56132. doi: 10.1371/journal.pone.0056132. Epub 2013 Feb 27.

14.

Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.

Fuchs O, Provaznikova D, Marinov I, Kuzelova K, Spicka I.

Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):62-77. Review.

PMID:
19275578
15.

Carfilzomib for the treatment of multiple myeloma.

Lue J, Goel S, Mazumder A.

Drugs Today (Barc). 2013 Mar;49(3):171-9. doi: 10.1358/dot.2013.49.3.1939264.

PMID:
23527321
16.

The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.

Bono C, Karlin L, Harel S, Mouly E, Labaume S, Galicier L, Apcher S, Sauvageon H, Fermand JP, Bories JC, Arnulf B.

Haematologica. 2012 Jul;97(7):1101-9. doi: 10.3324/haematol.2011.049981. Epub 2012 Jan 22.

17.

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.

Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, O'Donnell E, Selig MK, Quayle SN, Arastu-Kapur S, Kirk C, Boise LH, Jones SS, Raje N.

Br J Haematol. 2015 May;169(3):423-34. doi: 10.1111/bjh.13315. Epub 2015 Feb 23.

PMID:
25709080
18.

Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.

Berkers CR, Leestemaker Y, Schuurman KG, Ruggeri B, Jones-Bolin S, Williams M, Ovaa H.

Mol Pharm. 2012 May 7;9(5):1126-35. doi: 10.1021/mp2004143. Epub 2012 Apr 16.

PMID:
22432738
19.

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC.

Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8567-72. Epub 2005 Jun 3.

20.

In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.

Xu X, Yang J, Tang Y, Li J, Zhu Y, Lu H, Fei X.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6705-15. eCollection 2014.

Supplemental Content

Support Center